Correction of Psoriatic T Cell Signatures by Deucravacitinib

a study on Psoriasis

Summary

Eligibility
for people ages 18-75 (full criteria)
Location
at San Francisco, California
Dates
study started
completion around
Principal Investigator
by Raymond Cho, MD, PhD
Headshot of Raymond Cho
Raymond Cho

Description

Summary

This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the Tyrosine kinase 2 (TYK2) blocker, deucravacitinib.

Details

This is a one-arm, open-label study to examine the effect of deucravacitinib on cutaneous and blood immune cells of psoriatic patients. 25 subjects with moderate to severe psoriasis will be enrolled. Biopsy and blood samples will be collected before and during treatment and undergo molecular profiling to assess for deucravacitinib-corrected signatures.

Keywords

Psoriasis Vulgaris, Psoriasis, Deucravacitinib

Eligibility

You can join if…

Open to people ages 18-75

  1. 18 years of age or older
  2. Patients with moderate-severe psoriasis (BSA >= 10%, PASI >=12, static Physician's Global Assessment (sPGA) 3 and above)

You CAN'T join if...

  1. taking systemic immunosuppressives in the last 12 weeks
  2. pregnancy
  3. severe immunodeficiency (either from genetic or infectious causes).
  4. tuberculosis or other active serious infection
  5. active systemic malignancy.
  6. breast-feeding
  7. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.

Location

  • UCSF accepting new patients
    San Francisco California 94115 United States

Lead Scientist at UCSF

  • Raymond Cho, MD, PhD
    Dr. Cho is a physician and geneticist who investigates the molecular basis of skin disease. With colleague Dr. Jeffrey Cheng, he co-leads the RashX initiative at UCSF, which develops high resolution molecular fingerprints to understand and treat unusual skin diseases.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, San Francisco
ID
NCT05858645
Phase
Phase 4 Psoriasis Research Study
Study Type
Interventional
Participants
Expecting 25 study participants
Last Updated
Contact us about this trial